Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Innovation Center Exploring ‘Array’ Of Cost-Lowering Medicare Payment Models

Executive Summary

CMMI payment demonstrations are viewed as way of skirting statutory obstacles to experimenting with new approaches to reimbursement and could lead to significant drug pricing reforms if legislative efforts fail. However, HHS is not signaling an intent to pursue transformational new models at this point.

You may also be interested in...



HHS Drug Pricing Plan: Mum On National Cost Effectiveness Program, Cautious On QALYs

Biopharma likely approves of the Administration’s concern that QALYs, a commonly used metric in cost effectiveness evaluations, may not be appropriate for drug pricing reform policies because it could disadvantage people with disabilities.

CMS Scraps ‘Most Favored Nation’ Rule To Lower Medicare Part B Drug Costs

US Centers For Medicare and Medicaid Services doesn’t tip its hand on what, if anything, might replace the rule but says it is exploring ways to lower spending on Medicare Part B drugs.

Drug Pricing Reform: Now It Is HHS Secretary Becerra’s Turn

After months of reticence about his Administration's plans for tackling drug pricing, Biden's executive order offers some clues about what might be in store and what kind of timeline they are working with. 

Related Content

Topics

UsernamePublicRestriction

Register

PS144923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel